These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28705057)

  • 1. Applicability and procedural success rate of bioresorbable -vascular scaffolds for percutaneous coronary intervention in an all-comer cohort of 383 consecutive patients.
    Schlundt C; Achenbach S; Felten F; Roether J; Marwan M; Nef H; Ludwig J; Tröbs M
    Acta Cardiol; 2017 Aug; 72(4):425-432. PubMed ID: 28705057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
    Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
    Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.
    Naganuma T; Colombo A; Lesiak M; Capodanno D; Gori T; Nef H; Caramanno G; Naber C; Di Mario C; Ruparelia N; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Kawamoto H; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Latib A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):47-56. PubMed ID: 27414021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?
    Picard F; Avram R; Marquis-Gravel G; Tadros VX; Ly HQ; Dorval JF; Doucet S; Gosselin G; Asgar AW; Ibrahim R; Bonan R; de Hemptinne Q; Nosair M; L-L'Allier P; Tanguay JF
    Cardiovasc Revasc Med; 2019 Mar; 20(3):228-234. PubMed ID: 30075958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
    Baumbach A; Zaman A; West NEJ; O'Kane P; Egred M; Johnson T; Wheatcroft S; Bowles R; de Belder A; Bouras G; Lansky A; Hill J; Mathur A; de Belder MA; Banning AP
    EuroIntervention; 2018 Jan; 13(13):1554-1560. PubMed ID: 29131802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial.
    Rampat R; Mayo T; Hildick-Smith D; Cockburn J
    Cardiovasc Revasc Med; 2019 Jan; 20(1):43-49. PubMed ID: 30170828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
    de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy.
    Wöhrle J; Nef HM; Naber C; Achenbach S; Riemer T; Mehilli J; Münzel T; Schneider S; Markovic S; Seeger J; Rottbauer W; Pfannebecker T; Richardt G; Zahn R; Gori T; Kastner J; Schmermund A; Hamm CW;
    Coron Artery Dis; 2018 Aug; 29(5):389-396. PubMed ID: 29649071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry.
    Cayla G; Koning R; Fajadet J; Sainsous J; Carrié D; Elhadad S; Tarragano F; Lefévre T; Ranc S; Ghostine S; Garot P; Marco F; Maillard L; Motreff P; Le Breton H;
    Arch Cardiovasc Dis; 2019 Feb; 112(2):113-123. PubMed ID: 30630761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography.
    Grundeken MJ; Hassell ME; Kraak RP; de Bruin DM; Koch KT; Henriques JP; van Leeuwen TG; Tijssen JG; Piek JJ; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Dec; 11(8):877-84. PubMed ID: 25169592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct bioresorbable vascular scaffold implantation: Feasibility and midterm results.
    Suárez de Lezo J; Martín P; Mazuelos F; Nóvoa J; Ojeda S; Pan M; Segura J; Hernández E; Romero M; Melián F; Medina A; Suárez de Lezo J
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):E173-82. PubMed ID: 26268440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two-year results from the German-Austrian ABSORB registry.
    Tröbs M; Achenbach S; Nef HM; Gori T; Naber C; Neumann T; Richardt G; Schmermund A; Wöhrle J; Zahn R; Hamm CW;
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E564-E570. PubMed ID: 34137482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.